BMED iShares Health Innovation Active ETF
ETF on NYSE (US) · Actively managed · Listing
Changes appear once four weeks of holdings are on file.
Largest holding: Gilead Sciences, Inc., 5,033 shares ($843K).
| Current positions Top 10 | % of book |
|---|---|
| Gilead Sciences, Inc. GILD $843K | 5.9% |
| Moderna, Inc. MRNA $748K | 5.2% |
| Danaher Corporation DHR $743K | 5.2% |
| BLK CSH FND TREASURY SL AGENCY XTSLA $720K | 5.0% |
| AbbVie Inc. ABBV $716K | 5.0% |
| Edwards Lifesciences Corporation EW $626K | 4.4% |
| Thermo Fisher Scientific Inc TMO $624K | 4.4% |
| Merck & Company, Inc. MRK $602K | 4.2% |
| Biogen Inc. BIIB $541K | 3.8% |
| Mettler-Toledo International, Inc. MTD $525K | 3.7% |
Slices are % of holdings value.
| Sectors | % of long value |
|---|---|
| Healthcare | 83.3% |
| Technology | 7.1% |
| Financial Services | 0.8% |
| Unclassified | 8.8% |
| Industries | % of long value |
|---|---|
| Biotechnology | 41.7% |
| Drug Manufacturers - General | 14.4% |
| Medical Devices | 11.4% |
| Medical Instruments & Supplies | 8.8% |
| Scientific & Technical Instruments | 4.3% |
| Health Information Services | 4.3% |
| Software - Application | 2.8% |
| Other (2) | 3.5% |
| Unclassified | 8.8% |
Source: the fund's own published holdings, the portfolio of Nov 16, 2026 (ishares.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Dec 3, 2025.
The iShares Health Innovation Active ETF (the "Fund") seeks to maximize total return.
Principal investment strategies
Under normal market conditions, the Fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. Investments in derivatives are counted toward the Fund's 80% policy to the extent that they provide investment exposure to the securities included within that policy or to one or more market risk factors associated with such securities. The Fund seeks to invest in innovative and emerging companies in health sciences. The Fund will consider a company to be principally engaged in the health sciences group of industries if (i) it is classified in an industry within the health sciences group of industries by a third-party industry classification system or (ii) it is not classified in any industry by such third-party industry classification system and BFA determines that the company is principally engaged in the health sciences group of industries. Companies in the health sciences group of industries include healthcare providers as well as businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment or services or that provide support services to these companies. These companies also include those that own or operate health facilities and hospitals or provide related administrative, management or S-2 financial support. Other companies in the health sciences group of industries in which the Fund may invest include: clinical testing laboratories; diagnostics; hospital, laboratory or physician ancillary products and support services; rehabilitation services; employer health insurance management services; and vendors of goods and services specifically to companies engaged in the health sciences. The Fund will concentrate its investments in the health sciences group of industries. While the Fund will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants. Non-human health sciences companies include those engaged in the development, production or distribution of products or services that: increase crop, animal and animal product yields by enhancing growth or increasing disease resistance; improve agricultural product characteristics, such as taste, appearance, nutritional content and shelf life; reduce the cost of producing agricultural products; or improve pet health. The Fund may invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. The Fund will focus its investments in mid- and small-capitalization companies. Foreign securities in which the Fund may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated. The Fund invests primarily in equity securities, including common stocks, preferred stocks, warrants and depository receipts, of health sciences companies and equity interests in real estate investment trusts ("REITs") that own hospitals. The Fund may invest in shares of companies through initial public offerings ("IPOs"). The Fund may also purchase convertible securities. The Fund may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter ("OTC") put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques (collectively, "Strategic Transactions").
Management and Contact
- Adviser
- BlackRock Fund Advisors
- Portfolio managers
-
Erin Xie and Xiang Liu (the "Portfolio Managers") are jointly and primarily responsible for the day-to-day management of the Fund.
Ms. Xie and Mr. Liu have been Portfolio Managers of the Fund since September 2020.
- Phone
- 1-800-474-2737
- [email protected]
- Website
- blackrock.com/prospectus
Track Record as of Jul 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | Since Inception | |
|---|---|---|
| Return Before Taxes )% | 1.81% | 0.15% |
| Return after Taxes on Distributions1 )% | 1.81% | 0.15% |
| Return after Taxes on Distributions and Sale of Fund Shares1 )% | 1.07% | 0.11% |
| MSCI ACWI Index (Net)2,3 (Index returns do not reflect deductions for fees, expenses or taxes, except for withholding taxes on r | 17.49% | 11.69% |
| STOXX Global Breakthrough Healthcare Index (Net)3,4 (Index returns do not reflect deductions for fees, expenses or taxes, except | 1.61% | 2.31% |
Holdings as of Nov 16, 2026
The full portfolio the fund publishes every business day on its website (ishares.com). Every line is listed: holdings we could identify link to their page, the rest (cash, options, swaps, private shares, securities we do not carry) are shown as the fund prints them. Short positions are negative. Change is the share count against Nov 13, 2026.
61 lines, 49 linked, weights sum to 100.01% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| GILEAD SCIENCES | GILD | Equity | 5,033 | 0 | 5.89% | $ 843.43K |
| MODERNA | MRNA | Equity | 3,476 | 0 | 5.22% | $ 748.279K |
| DANAHER | DHR | Equity | 3,232 | 0 | 5.19% | $ 743.069K |
|
BLK CSH FND TREASURY SL AGENCY
|
XTSLA | Money market | 720,000 | 0 | 5.03% | $ 720K |
| ABBVIE | ABBV | Equity | 2,431 | 0 | 5.00% | $ 716.051K |
| EDWARDS LIFESCIENCES | EW | Equity | 5,846 | 0 | 4.37% | $ 626.165K |
| THERMO FISHER SCIENTIFIC | TMO | Equity | 902 | 0 | 4.35% | $ 623.58K |
| BIOGEN | BIIB | Equity | 2,150 | 0 | 3.78% | $ 541.048K |
| METTLER TOLEDO | MTD | Equity | 304 | 0 | 3.67% | $ 525.087K |
| IQVIA HOLDINGS INC | IQV | Equity | 1,923 | 0 | 3.55% | $ 509.076K |
| VERTEX PHARMACEUTICALS | VRTX | Equity | 884 | 0 | 3.32% | $ 475.406K |
| MERCK & CO INC | MRK | Equity | 2,943 | +1,868 | 2.97% | $ 425.146K |
| ROCHE PS PAR AG | ROP | Equity | 853 | 0 | 2.90% | $ 416.055K |
| GENMAB SPONSORED ADR | GMAB | Equity | 7,231 | 0 | 2.60% | $ 372.903K |
| AMGEN INC | AMGN | Equity | 802 | 0 | 2.59% | $ 370.781K |
| AGILENT TECHNOLOGIES INC | A | Equity | 1,973 | 0 | 2.38% | $ 341.171K |
| NEUROCRINE BIOSCIENCES | NBIX | Equity | 1,990 | 0 | 2.30% | $ 328.967K |
| WATERS CORP | WAT | Equity | 710 | 0 | 2.25% | $ 321.928K |
| DEXCOM INC | DXCM | Equity | 3,881 | 0 | 2.21% | $ 316.728K |
|
USD CASH
|
USD | Cash short | -305,676 | +91,174 | -2.13% | $ -305.676K |
| ARGENX SE ADR | ARGX | Equity | 277 | 0 | 1.84% | $ 263.413K |
| HALOZYME THERAPEUTICS | HALO | Equity | 2,531 | 0 | 1.70% | $ 244.242K |
| CHARLES RIVER LABORATORIES INTERNA | CRL | Equity | 689 | 0 | 1.61% | $ 231.173K |
| INTUITIVE SURGICAL | ISRG | Equity | 486 | 0 | 1.49% | $ 212.747K |
| ZIMMER BIOMET HOLDINGS | ZBH | Equity | 2,076 | 0 | 1.47% | $ 210.527K |
| TEVA PHARMACEUTICAL INDUSTRIES | TEVA | Equity | 4,924 | 0 | 1.46% | $ 209.615K |
|
GALDERMA GROUP N AG
|
GALD | Equity | 896 | 0 | 1.42% | $ 203.94K |
| ROIVANT SCIENCES LTD | ROIV | Equity | 5,171 | 0 | 1.39% | $ 199.652K |
| ILLUMINA INC | ILMN | Equity | 995 | 0 | 1.38% | $ 197.01K |
| PFIZER | PFE | Equity | 6,812 | −547 | 1.37% | $ 196.594K |
| BRISTOL MYERS SQUIBB | BMY | Equity | 3,058 | 0 | 1.34% | $ 192.44K |
|
NOVARTIS AG
|
NOVN | Equity | 1,171 | 0 | 1.32% | $ 189.448K |
| JOHNSON & JOHNSON | JNJ | Equity | 650 | 0 | 1.28% | $ 183.658K |
| MERCK | MRK | Equity | 1,075 | 0 | 1.24% | $ 177.117K |
|
HKD CASH
|
HKD | Cash | 1,347,832 | +1,347,682 | 1.20% | $ 171.79K |
| GUARDANT HEALTH | GH | Equity | 1,166 | 0 | 1.17% | $ 167.939K |
| CYTOKINETICS | CYTK | Equity | 2,888 | 0 | 1.07% | $ 153.555K |
| BIOMARIN PHARMACEUTICAL | BMRN | Equity | 2,533 | 0 | 1.03% | $ 146.889K |
| UCB SA | UCB | Equity | 370 | 0 | 0.84% | $ 120.171K |
| TEMPUS AI CLASS A | TEM | Equity | 1,749 | 0 | 0.79% | $ 113.265K |
| ABBOTT LABORATORIES | ABT | Equity | 1,027 | −719 | 0.77% | $ 110.351K |
| PROTAGONIST THERAPEUTICS | PTGX | Equity | 866 | 0 | 0.75% | $ 108.103K |
| BRUKER | BRKR | Equity | 1,648 | 0 | 0.70% | $ 99.902K |
| AXSOME THERAPEUTICS | AXSM | Equity | 721 | 0 | 0.69% | $ 98.784K |
| VIRIDIAN THERAPEUTICS ORS | VRDN | Equity | 3,067 | 0 | 0.64% | $ 91.397K |
| ALKERMES | ALKS | Equity | 1,902 | 0 | 0.62% | $ 88.5K |
| DIANTHUS THERAPEUTICS | DNTH | Equity | 890 | 0 | 0.56% | $ 79.7K |
| PTC THERAPEUTICS | PTCT | Equity | 1,001 | 0 | 0.43% | $ 61.031K |
| MBX BIOSCIENCES | MBX | Equity | 1,103 | 0 | 0.41% | $ 58.591K |
| COGENT BIOSCIENCES | COGT | Equity | 1,813 | 0 | 0.35% | $ 49.749K |
| SAGIMET BIOSCIENCES SERIES A | SGMT | Equity | 1,875 | 0 | 0.13% | $ 18.994K |
| SUMMIT THERAPEUTICS | SMMT | Equity | 706 | 0 | 0.06% | $ 8,344.92 |
| EIKON THERAPEUTICS | EIKN | Equity | 1,392 | 0 | 0.05% | $ 7,495.92 |
|
ABIOMED CVRS
|
- | Equity | 246 | +136 | 0.00% | $ 371.46 |
|
MIRATI THERAPEUTICS INC
|
MRTX | Equity | 334 | 0 | 0.00% | $ 260.52 |
|
GBP CASH
|
GBP | Cash | 127 | 0 | 0.00% | $ 168.04 |
|
BLUEPRINT MEDICINES CORP
|
- | Equity | 110 | 0 | 0.00% | $ 108.90 |
|
VIGIL NEUROSCIENCE INC CVR
|
DUMMY | Equity | 484 | 0 | 0.00% | $ 24.20 |
|
KRW CASH
|
KRW | Cash | 9 | 0 | 0.00% | $ 0.01 |
|
KORRO BIO INC CVR
|
KRRBIO | Equity | 420 | 0 | 0.00% | $ 0.00 |
| HKD/USD | HKD | Equity short | -1,347,750 | new −1,347,750 | 0.00% | $ -13.57 |
Trades Nov 13, 2026 to Nov 16, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
|
WUXI BIOLOGICS CAYMAN
|
2269 | Closed | 29,000 | — | −29,000 | $ -172.785K |
| ABBOTT LABORATORIES | ABT | Sold | 1,746 | 1,027 | −719 | $ -77.257K |
| PFIZER | PFE | Sold | 7,359 | 6,812 | −547 | $ -15.786K |
| HKD/USD | HKD | New | — | -1,347,750 | −1,347,750 | $ -13.57 |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up